bluebird bio (BLUE) Late-Breaker ASH Abstract Provides Proof-Of-Concept - Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Affirms bluebird bio (BLUE) at 'Outperform'; Late-Breaking ASH Data Bodes Will for bb2121
November 16, 2015 12:40 PM ESTWedbush affirms bluebird bio (Nasdaq: BLUE) with an Pit[erfpr, ratomg amd $165 price target after the company reported Phase 1 results in a late-breaking abstract from a NCI-sponsored study of anti-BCMA CAR-T cells dosed in multiple myeloma patients.
Analyst David M. Nierengarten noted, At lower doses (0.3-1 x 106 cells), 1 patient demonstrated a partial response (PR)... More
